Charles River Laboratories International (CRL) to Release Earnings on Thursday

Charles River Laboratories International (NYSE:CRL) is scheduled to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Charles River Laboratories International to post earnings of $2.05 per share for the quarter. Charles River Laboratories International has set its FY24 guidance at $10.90-11.40 EPS and its FY 2024 guidance at 10.900-11.400 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business’s quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.98 EPS. On average, analysts expect Charles River Laboratories International to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Charles River Laboratories International Price Performance

Shares of CRL opened at $235.27 on Tuesday. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The company’s fifty day simple moving average is $252.23 and its 200 day simple moving average is $224.47. Charles River Laboratories International has a 1-year low of $161.65 and a 1-year high of $275.00. The company has a market cap of $12.12 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 1.83 and a beta of 1.44.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CRL. UBS Group raised their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Evercore ISI raised their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. Robert W. Baird raised their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. increased their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Citigroup upped their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $253.23.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the sale, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 in the last 90 days. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).